Genzyme Corp. is among the world’s largest Biotechnology sector businesses in the world. Genzyme Corp.’s employees generate $40.4M in profits on $3.339B of revenue. Global output in the Biotechnology business will likely rise substantially over the next 10 years. Long-term economic growth may lift all boats, but Genzyme Corp. is determined to remain a market leader. Sectoral leadership in the Biotechnology segment takes dedication and consistency, but management seeks out-sized growth.
Genzyme Corp.’s ticker symbol GENZ has recently been trading near $65.64 a share. The Genzyme Corp. corporate headquarters in Cambridge MA predicts Biotechnology profits will satisfy shareholders in search of risk-appropriate returns.
The significance of market volume is sometimes ignored, but with a total market capitalization of $17.332B ensures sufficient liquidity. With a beta of 0.81, the company is less volatile than the market as a whole. When the average equity moves lower, Genzyme Corp. moves less aggressively.
Genzyme Corp.’s ticker symbol GENZ has recently been trading near $65.64 a share. The Genzyme Corp. corporate headquarters in Cambridge MA predicts Biotechnology profits will satisfy shareholders in search of risk-appropriate returns.
The significance of market volume is sometimes ignored, but with a total market capitalization of $17.332B ensures sufficient liquidity. With a beta of 0.81, the company is less volatile than the market as a whole. When the average equity moves lower, Genzyme Corp. moves less aggressively.
